Author:
Ehrenforth Silke,Seremetis Stephanie
Reference156 articles.
1. Abshire, T. C., Brackmann, H. H., Scharrer, I., Hoots, K., Gazengel, C., Powell, J. S., Gorina, E., Kellermann, E., and Vosburgh, E. 2000. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb. Haemost. 83:811–816.
2. Abshire, T. and Kenet, G. 2004. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J. Thromb. Haemost. 2:899–909.
3. Addiego, J. E. Jr., Gomperts, E., Liu, S.-L., Bailey, P., Courter, S. G., Lee, M. L., Neslund, G. G., Kingdon, H. S., and Griffith, M. J. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII immunoaffinity chromatography. Thromb. Haemost. 67:19–27.
4. Addiego, J. E., Kasper, C., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B., and Aledort, L. 1993. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 342:462–464.
5. Addiego, J. E., Kasper, C., Abildgaard, C., Lusher, J., Hilgartner, M., Glader, B., Aledort, L., Hurst, D., and Bray, G. 1994. Increased frequency of inhibitors in African American hemophilic patients. Blood 1:293a.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献